Novartis case sets “precedent”, says FAS
Russia’s Federal Antimonopoly Service has accused Novartis of abusing its dominant position after the Swiss drugmaker hiked the price of a cancer drug by 35%.
To read more
Subscribe to Global Competition Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now